The International Clinical Trial Center Network (ICN) is led by a Steering Board consisting of representatives of all ten core members. The Steering Board is the responsible, decision-making body of the ICN. Important functions of the Steering Board are to define and manage principles, rules, strategy and operations. The Steering Board also decides on memberships and services offered.
The chairperson of the Steering Board is elected for a period of two years. The current chairperson is PD Dr. Gabriela Senti of University Hospital Zurich.
J. Spencer Goldsmith (MBA): President, Baim Institute for Clinical Research, Boston, USA
Prof. Dr. Ian Wilkinson: Director of the Cambridge Clinical Trial Unit, Cambridge University Hospitals NHS Foundation Trust, United Kingdom
Rainer Bredenkamp: Director of Clinical Trials Unit Freiburg, Albert-Ludwigs-University of Freiburg, Germany
Henry Yau, (MBA): Managing Director of Clinical Trials Centre, The Hong Kong University, China
Prof. Dr. Yagiz Üresin: Vice Director of the Center of Excellence for Clinical Research, Istanbul University, Turkey
Prof. Dr. Muneo Takatani: Head of Department R&D Alliances, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Japan
Dr. med. Christiane Blankenstein: Director of Münchner Studienzentrum, Hospital rechts der Isar, Technical University of Munich, Germany
Dr. Juncai Xu, Senior Vice President of Shanghai Clinical Research Center, China
Damien Hong, Chief Operating Officer of Singapore Clinical Research Institute, Singapore
Prof. Dr. med. Gabriela Senti, Head of Clinical Trials Center Zurich, University Hospital Zurich, Switzerland
The ICN operates as much as possible on a decentralized basis. A core team manages common operations and processes.